PMID- 34208071
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230920
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 13
IP  - 12
DP  - 2021 Jun 11
TI  - Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer.
LID - 10.3390/cancers13122922 [doi]
LID - 2922
AB  - Up to one third of all breast cancers are classified as the aggressive 
      HER2-positive subtype, which is associated with a higher risk of recurrence 
      compared to HER2-negative breast cancers. The HER2 hyperactivity associated with 
      this subtype drives tumor growth by up-regulation of mechanistic target of 
      rapamycin (mTOR) pathway activity and a metabolic shift to glycolysis. Although 
      inhibitors targeting the HER2 receptor have been successful in treating 
      HER2-positive breast cancer, anti-HER2 therapy is associated with a high risk of 
      recurrence and drug resistance due to stimulation of the PI3K-Akt-mTOR signaling 
      pathway and glycolysis. Combination therapies against HER2 with inhibition of 
      mTOR improve clinical outcomes compared to HER2 inhibition alone. Here, we review 
      the role of the HER2 receptor, mTOR pathway, and glycolysis in HER2-positive 
      breast cancer, along with signaling mechanisms and the efficacy of treatment 
      strategies of HER2-positive breast cancer.
FAU - Holloway, Ryan W
AU  - Holloway RW
AUID- ORCID: 0000-0002-9475-0130
AD  - Department of Biochemistry & Molecular Biology, Faculty of Medicine, Dalhousie 
      University, Halifax, NS B3H 4R2, Canada.
FAU - Marignani, Paola A
AU  - Marignani PA
AUID- ORCID: 0000-0001-8070-905X
AD  - Department of Biochemistry & Molecular Biology, Faculty of Medicine, Dalhousie 
      University, Halifax, NS B3H 4R2, Canada.
LA  - eng
GR  - 0/Dalhousie Medical Research Foundation/
GR  - 0/Breast Cancer Society of Canada/
PT  - Journal Article
PT  - Review
DEP - 20210611
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC8230691
OTO - NOTNLM
OT  - 2-deoxyglucose
OT  - HER2-positive breast cancer
OT  - Herceptin
OT  - LKB1
OT  - PI3K-Akt-mTOR signaling pathway
OT  - clinical diagnostics
OT  - glycolysis
OT  - mTOR
OT  - rapalog
OT  - trastuzumab
OT  - tumor recurrence
COIS- The authors declare no conflict of interest.
EDAT- 2021/07/03 06:00
MHDA- 2021/07/03 06:01
PMCR- 2021/06/11
CRDT- 2021/07/02 01:33
PHST- 2021/05/10 00:00 [received]
PHST- 2021/06/09 00:00 [revised]
PHST- 2021/06/10 00:00 [accepted]
PHST- 2021/07/02 01:33 [entrez]
PHST- 2021/07/03 06:00 [pubmed]
PHST- 2021/07/03 06:01 [medline]
PHST- 2021/06/11 00:00 [pmc-release]
AID - cancers13122922 [pii]
AID - cancers-13-02922 [pii]
AID - 10.3390/cancers13122922 [doi]
PST - epublish
SO  - Cancers (Basel). 2021 Jun 11;13(12):2922. doi: 10.3390/cancers13122922.